Patents by Inventor Bjorn Rydevik

Bjorn Rydevik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS
    Publication number: 20120244157
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: June 6, 2012
    Publication date: September 27, 2012
    Applicant: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
    Publication number: 20120093816
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: November 14, 2011
    Publication date: April 19, 2012
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 8057792
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: November 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
    Patent number: 7906481
    Abstract: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: March 15, 2011
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Soluble cytokine receptors TNF-? blocking antibodies for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7811990
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include a soluble cytokine receptor and/or a TNF-? blocking antibody.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 12, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
    Publication number: 20100150922
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 17, 2010
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
    Patent number: 7723357
    Abstract: Described herein are methods and compositions for the treatment of spinal disorders mediated by nucleus pulposus. The compositions can include thalidomide or a thalidomide derivative.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 25, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
    Patent number: 7708995
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: May 4, 2010
    Assignee: Sciaticon AB
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • USE OF CERTAIN DRUGS FOR TREATING NERVE ROOT INJURY
    Publication number: 20080213283
    Abstract: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorder.
    Type: Application
    Filed: April 14, 2008
    Publication date: September 4, 2008
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20080085274
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNT-? comprising an effective amount of a metalloproteinase inhibitor, as well as a method for treatment of such disorders, and the use of metallo-proteinase inhibitors in the preparation of pharmaceutical composition for such treatment.
    Type: Application
    Filed: April 20, 2007
    Publication date: April 10, 2008
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20080019964
    Abstract: The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.
    Type: Application
    Filed: January 3, 2007
    Publication date: January 24, 2008
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20070104711
    Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
    Type: Application
    Filed: September 14, 2006
    Publication date: May 10, 2007
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Patent number: 6649589
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: November 18, 2003
    Assignee: A+ Science AB (publ)
    Inventors: Kjell Olmarker, Björn Rydevik
  • Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
    Patent number: 6635250
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: October 21, 2003
    Assignee: A+ Science AB (publ)
    Inventors: Kjell Olmarker, Björn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20010055594
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
    Type: Application
    Filed: April 6, 2001
    Publication date: December 27, 2001
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20010027199
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
    Type: Application
    Filed: January 17, 2001
    Publication date: October 4, 2001
    Inventors: Kjell Olmarker, Bjorn Rydevik
  • Use of certain drugs for treating nerve root injury
    Publication number: 20010027175
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.
    Type: Application
    Filed: January 17, 2001
    Publication date: October 4, 2001
    Inventors: Kjell Olmarker, Bjorn Rydevik